TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection fraction <50%.

TCT 2024 | Utilización de balones cubiertos de fármacos para el tratamiento de la rama lateral en técnica de stent provisional

However, there is a significant group of patients with asymptomatic severe aortic stenosis. As such, they are advised to undergo clinical and echocardiographic follow-up. While there are some available studies regarding this scenario, current data is inconclusive.

The EARLY TAVR study—a prospective, multicenter, randomized trial—included 911 patients; of these, 455 underwent transcatheter aortic valve replacement (TAVR), and the rest were assigned to clinical follow-up (CF). The transcatheter aortic valve used was the SAPIEN 3 or SAPIEN 3 Ultra (Edwards Lifesciences).

The primary endpoint (PE) was a composite of all-cause mortality, stroke, and unplanned cardiovascular hospitalization.

Both groups had similar characteristics: the average age was 76 years, 30% of subjects were women, and the STS mortality score was 1.8%; 81% of patients had hypertension, 26% had diabetes, 5% had a history of heart attack, 4.2% had experienced a stroke, 14% had atrial fibrillation, 3% had chronic obstructive pulmonary disease (COPD), and 6% had an estimated glomerular filtration rate (eGFR) <45 mL/min.

Read also: TCT 2024 | FAVOR III EUROPA.

The mean ejection fraction was 67%, the aortic valve area was 0.9 cm², the mean gradient was 45 mmHg, the flow velocity was 4.6 m/s, and 8.5% of cases involved bicuspid valves.

With a follow-up of 3.8 (2.5-5) years, the PE favored the TAVR group (26.8% vs. 45.3%; hazard ratio: 0.50; 95% confidence interval [CI], 0.40 to 0.63; p <0.001). There were no differences in the incidence of all-cause mortality (8.4% vs. 9.2%) or stroke (4.2% vs. 6.3%), but there were fewer unplanned cardiovascular rehospitalizations in the TAVR group (20.9% vs. 41.7%).

Crossover to surgery in the clinical follow-up group was 86% at 3 years and 96% at 5 years.

Conclusion

Among patients with asymptomatic severe aortic stenosis, TAVR proved to be a superior strategy to clinical follow-up in reducing the incidence of death, stroke, or unplanned cardiovascular rehospitalization.

Original Title: Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. EARLY TAVR Trial.

Reference: P. Généreux, et al NEJM, October 28 DOI: 10.1056/NEJMoa2405880.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...